The RheumSafer Study: Improving Medication Appropriateness in People With Rheumatic Conditions

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age60+
SponsorMcGill University Health Centre/Research Institute of the McGill University Health Centre

About this trial

The goal of this prospective observational quality improvement study is to determine if a physician tool, MedSafer, combined with educational brochures for patients, can help to reduce the use of 'potentially inappropriate medications' (PIMs) in adults aged 60 and over with rheumatic conditions and polypharmacy (taking 5 or more regular medications).

Researchers will follow participants during usual rheumatic disease care. They will compare the rate of PIM deprescribing (stopping medications or reducing the dose) before and after the introduction of the following interventions:

* MedSafer reports provided to treating physicians * EMPOWER consumer brochures provided to participants

Participants will complete 4 study visits over 18-20 months during which researchers will collect information on medication changes, serious adverse events (emergency visits or hospitalizations), and quality of life.

Eligibility criteria

Qualifiers

Aged ≥60

Followed by a rheumatologist at MUHC for an inflammatory arthritis (such as rheumatoid arthritis, psoriatic arthritis, spondyloarthritis), a systemic autoimmune rheumatic disease (such as systemic lupus erythematosus, inflammatory myositis, systemic sclerosis, antiphospholipid antibody syndrome, Sjogren syndrome, systemic vasculitis), or another chronic musculoskeletal or rheumatic condition (such as crystal arthritis and osteoarthritis)

Currently taking ≥5 regular medications and ≥1 PIM

Anticipated ongoing clinical follow-up in rheumatology at an interval of every 3-9 months

Disqualifiers

Unable to provide informed consent

Acute life-threatening illness or life expectancy <12 months

Trial design

Treatments tested in this trial

  • MedSafer deprescribing opportunity reports, EMPOWER brochures

Treatment groups

100 Participants
are divided into 1 treatment group

Sponsors and collaborators